Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell SAJ, Schmidt MS, Weidemann BJ, et al.
Key finding
NR is orally bioavailable in humans and raises blood NAD+ without flushing. Source: Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nature Communications, 2016.
Summary
First human pharmacokinetic data for NR. Single oral doses of 100-1,000 mg raised blood NAD+ in a dose-dependent fashion without flushing or adverse events.
For background on the compound studied here, see our NR precursor reference.
Frequently asked questions
- What did Trammell et al. (2016) find about NR?
- NR is orally bioavailable in humans and raises blood NAD+ without flushing. Source: Trammell SAJ, Schmidt MS, Weidemann BJ, et al. "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans." Nature Communications, 2016.
- What kind of study is Trammell 2016?
- It is a pk study on NR published in Nature Communications in 2016. First human pharmacokinetic data for NR. Single oral doses of 100-1,000 mg raised blood NAD+ in a dose-dependent fashion without flushing or adverse events.
- Where can I read the full Trammell 2016 paper?
- The primary source is available on PubMed (PMID 27721479) and via DOI 10.1038/ncomms12948.
Access the full paper
Related research
Cell Reports · 2019
Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome
NR raises tissue NAD+ in aged muscle and shifts mitochondrial transcription.
Scientific Reports · 2019
Safety and metabolism of long-term administration of NIAGEN (Nicotinamide Riboside Chloride) in healthy middle-aged and older adults
NR is well tolerated at doses up to 1 g/day over 8 weeks in healthy adults.
Nature Communications · 2018
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
NR at 1 g/day raises NAD+ ~60% and may reduce systolic BP in adults with Stage 1 hypertension.